Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.G. Belbute
Pdb67 - Once-Weekly Semaglutide Versus Dulaglutide for the Treatment of Patients With Type 2 Diabetes in Portugal: A Long-Term Cost-Effectiveness Analysis Based on Sustain 7
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pdb87 - A Cost-Of-Control Analysis: Once-Weekly Semaglutide Reduces Cost of Reaching Treatment Targets in Patients With Type 2 Diabetes Mellitus in Norway
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Dulaglutide: Third Once-Weekly GLP-1 Agonist for Type 2 Diabetes
Pharmacy Today
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
Advances in Therapy
Medicine
Pharmacology
The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Common OAD: A Subgroup Analysis From SUSTAIN 2–4 and 10
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
Exenatide Extended-Release: A Once Weekly Treatment for Patients With Type 2 Diabetes
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial
The Lancet Diabetes and Endocrinology
Internal Medicine
Endocrinology
Metabolism
Diabetes
Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial
The Lancet Diabetes and Endocrinology
Internal Medicine
Endocrinology
Metabolism
Diabetes
Pdb74 - Ideglira Versus Iglarlixi for Patients With Inadequately Controlled Type 2 Diabetes on Basal Insulin: A Long-Term Cost-Effectiveness Analysis in the Czech Republic
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
